What is Ixabepilone? Function and use

Ixabepilone is an anti-tumor drug that belongs to the epimicrotubule inhibitor class. It was approved by the US FDA in October 2007 for the treatment of patients with metastatic or locally advanced breast cancer who are no longer sensitive to conventional chemotherapy. As the first approved epipodin inhibitor derivative, ixabepilone represents a breakthrough in a new generation of microtubule-targeting drugs. Its core mechanism is to bind to microtubules and promote abnormal stabilization of microtubules, thereby inhibiting cell division and ultimately leading to tumor cell apoptosis. Compared with traditional taxane drugs, ixabepilone still shows better activity in drug-resistant tumor cells, so it is considered an important supplement for the treatment of advanced breast cancer.

In terms of specific uses, ixabepilone is mainly used for breast cancer patients who have failed previous treatments with anthracyclines, taxanes, capecitabine and other drugs. Since breast cancer is a highly heterogeneous malignant tumor, different molecular subtypes have greatly different sensitivities to chemotherapy drugs. Many patients are prone to drug resistance and disease progression after multi-line treatment. It is against this background that ixabepilone is used clinically. It is often used in combination with capecitabine to improve treatment response rates, while single-agent regimens are also used in some refractory cases.

It should be emphasized that ixabepilone is not a first-line drug for breast cancer, but is a rescue treatment option with the purpose of delaying disease progression and improving quality of life. International clinical experience shows that although the drug may cause certain bone marrow suppression and neurotoxicity, the overall safety is controllable. Under the concept of precision medicine, doctors will reasonably choose whether to use ixabepilone based on the patient's past treatment history, molecular classification and overall health status. As breast cancer treatment gradually expands from single chemotherapy to targeted therapy and immunotherapy, ixabepilone remains a key option in multi-line chemotherapy and occupies an irreplaceable position in the spectrum of tumor drugs.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html